OX413 / Valerio Therap - LARVOL DELTA

Anticancer effects of PARP1 hyperactivation by a new generation of decoy oligodeoxynucleotide (ESMO 2022) - "In MPA/DMBA-driven tumors, OX413 mediated considerable anticancer effects that could be exacerbated by PD1 inhibition. Conclusions Our results provide preclinical rationale for using OX413 to trigger metabolic exhaustion in cancer cells and initiate inflammatory responses that can be actioned by immune checkpoint inhibitors in patients bearing HRD as well as HRP tumors."

Breast Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor

Anticancer effects of PARP1 hyperactivation by a decoy oligodeoxynucleotide in vitro and in vivo. (ASCO 2022) - "Our results provide preclinical rationale for using OX413 to trigger metabolic exhaustion in cancer cells and initiate inflammatory responses that can be actioned by immune checkpoint inhibitors in patients bearing HRD as well as HRP tumors."

Preclinical • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • Immune Modulation • Inflammation • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • HER-2

[VIRTUAL] A new generation of PARP interfering drug candidates for cancer treatment (AACR 2021) - "This breakthrough decoy agonist action has already shown, using our lead compound AsiDNA™, target engagement, excellentsafety profile in humans, and importantly lack of acquired resistance. Our results provide a preclinical rationale for using OX413 as an immunomodulatory and “metabolic exhauster” agent, especially in appropriately molecularly selected patients with tumors showing metabolic deficiencies."

Breast Cancer • Oncology • Solid Tumor • CD8 • PARP1 • PTPRC

Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update (GlobeNewswire) - "The preclinical proof of concept of one or more OX400 compounds, expected in 2021, will be the starting point for the activities necessary for entry into the clinic, potentially in combination with immunotherapy, within 12 to 18 months."

Preclinical • Oncology

Onxeo to Present New Preclinical Data at AACR 2021 (GlobeNewswire) - "Onxeo S.A...announced the presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates generated by platON™...in e-poster sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April 10, 2021. The first e-poster supports the ability of AsiDNA™...to prevent resistance to KRAS inhibitors (KRASi) emerging from drug-tolerant persister cells (DTC)...The second e-poster describes the mechanism of action of the molecules of the new OX400 family, specifically designed to interfere with PARP signaling and display immunomodulatory properties and metabolic effects."

Preclinical • Oncology